113 is the total number of securities Samsara BioCapital, LLC has owned. The longest Samsara BioCapital, LLC has owned a single stock is 20 quarters.
Period | Weighting | Quarter | |||||||
---|---|---|---|---|---|---|---|---|---|
Ticker | Name | Longest | Shortest | Min. | Avg. | Max. | First | Latest | ↓ Count |
ICPT | Intercept Pharmaceutic... | 20 | 20 | 1.00% | 7.53% | 23.97% | Q4 2018 | Q3 2023 | 20 |
ALLK | ALLAKOS INC | 20 | 20 | 0.12% | 5.22% | 23.00% | Q4 2018 | Q3 2023 | 20 |
STRO | SUTRO BIOPHARMA INC | 20 | 20 | 1.37% | 4.83% | 10.08% | Q4 2018 | Q3 2023 | 20 |
SYRS | SYROS PHARMACEUTICALS INC | 16 | 16 | 0.49% | 4.08% | 11.58% | Q4 2018 | Q3 2022 | 16 |
BCEL | ATRECA INC | 16 | 16 | 0.06% | 2.00% | 7.36% | Q2 2019 | Q1 2023 | 16 |
ISEE | IVERIC BIO INC | 15 | 15 | 1.65% | 3.32% | 5.53% | Q4 2019 | Q2 2023 | 15 |
ACRS | ACLARIS THERAPEUTICS INC | 15 | 15 | 0.89% | 2.08% | 4.75% | Q1 2020 | Q3 2023 | 15 |
RYTM | RHYTHM PHARMACEUTICALS... | 15 | 15 | 0.38% | 1.30% | 2.42% | Q1 2020 | Q3 2023 | 15 |
ODT | ODONATE THERAPEUTICS INC | 14 | 14 | 0.18% | 5.14% | 14.93% | Q4 2018 | Q1 2022 | 14 |
SWTX | SPRINGWORKS THERAPEUTI... | 14 | 14 | 0.12% | 3.94% | 12.05% | Q3 2019 | Q4 2022 | 14 |
VRNA | VERONA PHARMA PLC | 14 | 14 | 0.06% | 1.61% | 3.91% | Q2 2020 | Q3 2023 | 14 |
NKTX | NKARTA INC | 13 | 13 | 1.10% | 7.47% | 17.06% | Q3 2020 | Q3 2023 | 13 |
AGLE | AEGLEA BIOTHERAPEUTICS... | 13 | 13 | 0.05% | 0.79% | 2.88% | Q2 2020 | Q2 2023 | 13 |
ALVR | ALLOVIR INC | 13 | 13 | 0.05% | 0.21% | 0.70% | Q3 2020 | Q3 2023 | 13 |
AVDL | AVADEL PHARMACEUTICALS... | 12 | 12 | 0.29% | 1.28% | 3.05% | Q4 2020 | Q3 2023 | 12 |
NVAX | NOVAVAX INC | 12 | 12 | 0.03% | 0.46% | 1.01% | Q3 2020 | Q2 2023 | 12 |
KALA | KALA PHARMACEUTICALS INC | 12 | 12 | 0.03% | 0.40% | 1.15% | Q1 2020 | Q4 2022 | 12 |
KRON | KRONOS BIO INC | 12 | 12 | 0.02% | 0.21% | 0.90% | Q4 2020 | Q3 2023 | 12 |
NGM | NGM BIOPHARMACEUTICALS... | 12 | 12 | 0.01% | 0.08% | 0.31% | Q2 2020 | Q1 2023 | 12 |
KDNY | CHINOOK THERAPEUTICS INC | 11 | 11 | 5.05% | 17.84% | 34.81% | Q4 2020 | Q2 2023 | 11 |
BOLT | BOLT BIOTHERAPEUTICS INC | 11 | 11 | 0.24% | 0.99% | 4.48% | Q1 2021 | Q3 2023 | 11 |
IMCR | Immunocore Holdings Li... | 11 | 11 | 0.31% | 0.85% | 1.60% | Q1 2021 | Q3 2023 | 11 |
EYPT | EYEPOINT PHARMACEUTICA... | 11 | 11 | 0.29% | 0.81% | 1.47% | Q1 2021 | Q3 2023 | 11 |
Catabasis Pharmaceutic... | 11 | 11 | 0.04% | 0.79% | 1.87% | Q4 2018 | Q2 2021 | 11 | |
VIRX | VIRACTA THERAPEUTICS INC | 11 | 11 | 0.17% | 0.63% | 1.42% | Q1 2021 | Q3 2023 | 11 |
EQ | EQUILLIUM INC | 11 | 11 | 0.09% | 0.59% | 1.73% | Q3 2020 | Q1 2023 | 11 |
TERN | TERNS PHARMACEUTICALS INC | 11 | 11 | 0.19% | 0.52% | 2.02% | Q1 2021 | Q3 2023 | 11 |
GRPH | GRAPHITE BIO INC | 10 | 10 | 3.86% | 10.97% | 28.19% | Q2 2021 | Q3 2023 | 10 |
FMTX | Forma Therapeutics Hol... | 10 | 10 | 2.88% | 8.37% | 23.60% | Q2 2020 | Q3 2022 | 10 |
TIL | INSTIL BIO INC | 10 | 10 | 0.17% | 3.52% | 7.19% | Q1 2021 | Q2 2023 | 10 |
RAIN | RAIN THERAPEUTICS INC | 10 | 10 | 0.43% | 2.58% | 4.08% | Q2 2021 | Q3 2023 | 10 |
JANX | JANUX THERAPEUTICS INC | 10 | 10 | 0.75% | 1.24% | 1.87% | Q2 2021 | Q3 2023 | 10 |
DBTX | DECIBEL THERAPEUTICS INC | 10 | 10 | 0.35% | 0.79% | 1.73% | Q1 2021 | Q2 2023 | 10 |
DAWN | DAY ONE BIOPHARMACEUTI... | 10 | 10 | 0.41% | 0.69% | 0.94% | Q2 2021 | Q3 2023 | 10 |
ALBO | ALBIREO PHARMA INC | 10 | 10 | 0.38% | 0.55% | 0.93% | Q3 2020 | Q4 2022 | 10 |
KALV | KalVista Pharmaceutica... | 9 | 9 | 0.13% | 1.22% | 2.84% | Q4 2018 | Q4 2020 | 9 |
TANGO THERAPEUTICS INC | 9 | 9 | 0.37% | 1.03% | 2.17% | Q3 2021 | Q3 2023 | 9 | |
ELEV | ELEVATION ONCOLOGY INC | 9 | 9 | 0.17% | 0.63% | 1.56% | Q2 2021 | Q2 2023 | 9 |
RCKT | ROCKET PHARMACEUTICALS... | 9 | 9 | 0.16% | 0.47% | 1.03% | Q1 2020 | Q1 2022 | 9 |
AMRN | AMARIN CORP PLC | 9 | 9 | 0.01% | 0.08% | 0.45% | Q1 2020 | Q1 2022 | 9 |
JYAC | JIYA ACQUISITION CORP | 8 | 8 | 0.62% | 7.25% | 50.99% | Q4 2020 | Q3 2022 | 8 |
CNTA | CENTESSA PHARMACEUTICA... | 8 | 8 | 1.13% | 2.74% | 4.26% | Q2 2021 | Q1 2023 | 8 |
NVAX | NOVAVAX INC | 8 | 8 | 0.05% | 2.22% | 6.64% | Q1 2021 | Q4 2022 | 8 |
IO BIOTECH INC | 8 | 8 | 0.35% | 0.95% | 1.57% | Q4 2021 | Q3 2023 | 8 | |
UROV | Urovant Sciences Ltd | 8 | 8 | 0.41% | 0.87% | 1.24% | Q4 2018 | Q3 2020 | 8 |
BLSA | BCLS ACQUISITION CORP | 8 | 8 | 0.34% | 0.57% | 0.79% | Q4 2020 | Q3 2022 | 8 |
SCIENCE 37 HOLDINGS INC | 8 | 8 | 0.03% | 0.56% | 2.18% | Q4 2021 | Q3 2023 | 8 | |
VTVT | VTV THERAPEUTICS INC | 8 | 8 | 0.21% | 0.28% | 0.37% | Q4 2021 | Q3 2023 | 8 |
ASTRIA THERAPEUTICS INC | 8 | 8 | 0.02% | 0.05% | 0.08% | Q3 2021 | Q2 2023 | 8 | |
PRNB | Principia Biopharma Inc | 7 | 7 | 6.60% | 9.21% | 13.70% | Q4 2018 | Q2 2020 | 7 |
SRRK | SCHOLAR ROCK HLDG CORP | 7 | 7 | 1.10% | 6.84% | 10.00% | Q1 2022 | Q3 2023 | 7 |
ARCELLX INC | 7 | 7 | 3.41% | 5.09% | 6.74% | Q1 2022 | Q3 2023 | 7 | |
ARAV | Aravive Inc | 7 | 7 | 1.50% | 2.26% | 3.77% | Q4 2018 | Q2 2020 | 7 |
HOOK | Hookipa Pharma Inc | 7 | 7 | 0.14% | 1.81% | 3.11% | Q2 2019 | Q4 2020 | 7 |
IGMS | IGM BIOSCIENCES INC | 7 | 7 | 0.25% | 0.61% | 1.04% | Q1 2022 | Q3 2023 | 7 |
SURROZEN INC | 7 | 7 | 0.04% | 0.20% | 0.38% | Q3 2021 | Q1 2023 | 7 | |
BNTX | BIONTECH SE | 7 | 7 | 0.09% | 0.19% | 0.25% | Q3 2020 | Q1 2022 | 7 |
LQDA | Liquidia Technologies Inc | 6 | 6 | 0.37% | 3.69% | 7.87% | Q4 2018 | Q1 2020 | 6 |
HILLEVAX INC | 6 | 6 | 1.81% | 2.34% | 3.29% | Q2 2022 | Q3 2023 | 6 | |
LYRA | LYRA THERAPEUTICS INC | 6 | 6 | 0.74% | 2.00% | 3.33% | Q2 2022 | Q3 2023 | 6 |
PEPGEN INC | 6 | 6 | 1.01% | 1.44% | 1.87% | Q2 2022 | Q3 2023 | 6 | |
DICE THERAPEUTICS INC | 6 | 6 | 1.05% | 1.26% | 1.65% | Q1 2022 | Q2 2023 | 6 | |
MLND | Millendo Therapeutics Inc | 6 | 6 | 0.34% | 1.12% | 2.31% | Q4 2018 | Q1 2020 | 6 |
VTGN | VISTAGEN THERAPEUTICS INC | 6 | 6 | 0.15% | 0.31% | 0.72% | Q4 2020 | Q1 2022 | 6 |
NUVBWS | NUVATION BIO INC | 6 | 6 | 0.00% | 0.01% | 0.01% | Q2 2022 | Q3 2023 | 6 |
SURROZEN INC | 6 | 6 | 0.00% | 0.00% | 0.01% | Q2 2022 | Q3 2023 | 6 | |
RXRX | Recursion Pharmaceutic... | 5 | 5 | 0.58% | 1.91% | 3.50% | Q2 2021 | Q2 2022 | 5 |
SNSS | Sunesis Pharmaceutical... | 5 | 5 | 0.96% | 1.75% | 3.58% | Q1 2019 | Q1 2020 | 5 |
ALXO | ALX ONCOLOGY HLDGS INC | 5 | 5 | 0.24% | 0.63% | 1.12% | Q1 2022 | Q1 2023 | 5 |
AMYT | AMRYT PHARMA PLC | 5 | 5 | 0.48% | 0.61% | 0.92% | Q1 2022 | Q1 2023 | 5 |
GOSS | GOSSAMER BIO INC | 3 | 1 | 1.56% | 5.12% | 9.08% | Q1 2019 | Q3 2023 | 4 |
ZYME | ZYMEWORKS INC | 4 | 4 | 1.37% | 1.78% | 2.74% | Q1 2022 | Q4 2022 | 4 |
EVLO | Evelo Biosciences Inc | 4 | 4 | 0.94% | 1.64% | 2.84% | Q4 2018 | Q3 2019 | 4 |
ALLK | ALLAKOS INC | 4 | 4 | 0.32% | 1.44% | 2.79% | Q1 2021 | Q4 2021 | 4 |
PRIME MEDICINE INC | 4 | 4 | 1.20% | 1.41% | 1.88% | Q4 2022 | Q3 2023 | 4 | |
IMTX | IMMATICS N.V | 4 | 4 | 0.71% | 0.96% | 1.40% | Q4 2022 | Q3 2023 | 4 |
BCTG | BCTG Acquisition Corp | 4 | 4 | 0.58% | 0.94% | 1.44% | Q3 2020 | Q2 2021 | 4 |
ALPN | Alpine Immune Sciences... | 4 | 4 | 0.31% | 0.70% | 1.21% | Q3 2020 | Q2 2021 | 4 |
SYROS PHARMACEUTICALS INC | 4 | 4 | 0.49% | 0.68% | 1.07% | Q4 2022 | Q3 2023 | 4 | |
MINERALYS THERAPEUTICS... | 3 | 3 | 13.16% | 13.77% | 14.63% | Q1 2023 | Q3 2023 | 3 | |
ZYMEWORKS INC | 3 | 3 | 2.21% | 2.69% | 3.03% | Q1 2023 | Q3 2023 | 3 | |
CVAC | CureVac N.V. | 3 | 3 | 0.78% | 2.40% | 4.81% | Q3 2020 | Q1 2021 | 3 |
BLU | Bellus Health Inc | 3 | 3 | 1.11% | 1.71% | 2.25% | Q4 2019 | Q2 2020 | 3 |
PIRS | Pieris Pharmaceuticals... | 3 | 3 | 1.22% | 1.67% | 2.13% | Q4 2019 | Q2 2020 | 3 |
AIMT | Aimmune Therapeutics, ... | 3 | 3 | 0.56% | 1.25% | 1.93% | Q1 2020 | Q3 2020 | 3 |
GERN | Genron Corporation | 3 | 3 | 0.20% | 1.22% | 2.73% | Q2 2020 | Q4 2020 | 3 |
FULC | Fulcrum Therapeutics, ... | 3 | 3 | 0.35% | 0.91% | 1.73% | Q2 2020 | Q4 2020 | 3 |
CHFWU | Consonance HFW Acquisi... | 3 | 3 | 0.32% | 0.41% | 0.54% | Q4 2020 | Q2 2021 | 3 |
LSAQ | Lifesci Acquisition II... | 3 | 3 | 0.22% | 0.28% | 0.37% | Q4 2020 | Q2 2021 | 3 |
SURF | Surface Oncology Inc | 3 | 3 | 0.15% | 0.25% | 0.32% | Q4 2018 | Q2 2019 | 3 |
Trillium Therapeutics Inc | 3 | 3 | 0.02% | 0.06% | 0.12% | Q4 2018 | Q2 2019 | 3 | |
ACELYRIN INC | 2 | 2 | 7.41% | 7.84% | 8.28% | Q2 2023 | Q3 2023 | 2 | |
INZY | INOZYME PHARMA INC | 1 | 1 | 0.60% | 1.30% | 2.01% | Q1 2023 | Q3 2023 | 2 |
PTLA | Portola Pharmaceutical... | 2 | 2 | 0.66% | 1.18% | 1.70% | Q1 2020 | Q2 2020 | 2 |
PANAU | Panacea Acquisition Corp. | 2 | 2 | 0.51% | 0.93% | 1.34% | Q3 2020 | Q4 2020 | 2 |
AKRO | Akero Therapeutics, Inc. | 2 | 2 | 0.18% | 0.39% | 0.61% | Q1 2020 | Q2 2020 | 2 |
LEAP THERAPEUTICS INC | 2 | 2 | 0.25% | 0.29% | 0.33% | Q2 2023 | Q3 2023 | 2 | |
PDSB | PDS Biotechnology Corp | 2 | 2 | 0.04% | 0.04% | 0.05% | Q1 2019 | Q2 2019 | 2 |
RAYZEBIO INC | 1 | 1 | 12.54% | 12.54% | 12.54% | Q3 2023 | Q3 2023 | 1 | |
UMRX | Unum Therapeutics, Inc. | 1 | 1 | 3.71% | 3.71% | 3.71% | Q3 2020 | Q3 2020 | 1 |
MGEN | Miragen Therapeutics Inc | 1 | 1 | 2.64% | 2.64% | 2.64% | Q4 2018 | Q4 2018 | 1 |
LIFE | ATYR PHARMA INC | 1 | 1 | 0.76% | 0.76% | 0.76% | Q1 2023 | Q1 2023 | 1 |
RGLS | Regulus Therapeutics Inc | 1 | 1 | 0.75% | 0.75% | 0.75% | Q2 2019 | Q2 2019 | 1 |
COGT | Cogent Biosciences Inc | 1 | 1 | 0.66% | 0.66% | 0.66% | Q4 2020 | Q4 2020 | 1 |
BLUE | Bluebird Bio Inc | 1 | 1 | 0.66% | 0.66% | 0.66% | Q1 2020 | Q1 2020 | 1 |
SLNO | Soleno Therapeutics, Inc. | 1 | 1 | 0.54% | 0.54% | 0.54% | Q2 2020 | Q2 2020 | 1 |
SPRO | Spero Therapeutics, Inc. | 1 | 1 | 0.50% | 0.50% | 0.50% | Q3 2020 | Q3 2020 | 1 |
ASMB | Assembly Biosciences Inc. | 1 | 1 | 0.22% | 0.22% | 0.22% | Q2 2020 | Q2 2020 | 1 |
SBTX | Silverback Therapeutic... | 1 | 1 | 0.12% | 0.12% | 0.12% | Q4 2020 | Q4 2020 | 1 |
KDMN | Kadmon Hldgs Inc | 1 | 1 | 0.07% | 0.07% | 0.07% | Q4 2020 | Q4 2020 | 1 |
LPTX | LEAP THERAPEUTICS INC | 1 | 1 | 0.06% | 0.06% | 0.06% | Q1 2023 | Q1 2023 | 1 |
EDGE | Edge Therapeutics Inc | 1 | 1 | 0.06% | 0.06% | 0.06% | Q4 2018 | Q4 2018 | 1 |
KALA PHARMACEUTICALS INC | 1 | 1 | 0.04% | 0.04% | 0.04% | Q1 2023 | Q1 2023 | 1 | |
Download |
The securities at the top of the list , including Intercept Pharmaceuticals Inc, ALLAKOS INC, and SUTRO BIOPHARMA INC, are the highest-conviction holdings of Samsara BioCapital, LLC.
The conviction is calculated by counting the number of quarters a security has been reported by Samsara BioCapital, LLC. The higher the number, the higher the conviction and longer the holding period.
This page lists all the securities that Samsara BioCapital, LLC owns currently or has owned in the past.